Business Context and Reporting Period
This Form 6-K filing by Evogene Ltd. covers the month of July 2024, with a specific report date of July 23, 2024. The filing primarily announces a corporate action regarding the Company's capital structure rather than reporting operational financial results.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on the mechanics of a reverse share split.
Material Changes
The primary material change is the implementation of a 1-for-10 reverse share split of the Company's ordinary shares. Key details include:
- Ratio: 10 existing shares will be consolidated into 1 new share.
- Par Value Adjustment: Par value increases from NIS 0.02 to NIS 0.20 per share.
- Effective Dates: Trading on the Nasdaq Capital Market is expected to resume on July 25, 2024, and on the Tel Aviv Stock Exchange on July 28, 2024.
- Share Count: Post-split, authorized capital will be 15 million shares, with approximately 5,079,000 shares issued and outstanding.
- Fractional Shares: No cash will be paid for fractional shares; they will be rounded to the nearest whole share based on a threshold of more than half a consolidated share.
- Equity Plans: Outstanding options and Restricted Share Units (RSUs) will be adjusted proportionately (exercise prices increased, share counts decreased).
Guidance, Outlook, and Risks
The filing does not contain financial guidance, management commentary on future performance, or specific risk factors beyond the standard mechanics of the share split. The document serves as a notification of the corporate action and incorporates the associated press release by reference.
Investor Verification Checklist
- Verify the exact timing of the reverse split implementation on Nasdaq (July 25) and TASE (July 28).
- Confirm the treatment of fractional shares held in brokerage accounts to ensure proper rounding.
- Review the adjusted terms of any outstanding stock options or RSUs held by employees or management.
- Check the updated number of authorized and outstanding shares (15 million authorized; ~5.08 million outstanding).